Phosphodiesterase 1, PDE1, EC 3.1.4.1, systematic name oligonucleotide 5 ′-nucleotidohydrolase) is a phosphodiesterase enzyme also known as calcium - and calmodulin -dependent phosphodiesterase. It is one of the 11 families of phosphodiesterase (PDE1-PDE11).

PDE1 is a dual substrate (cAMP and cGMP) diesterase and a promising target for the treatment of heart disease, cancer, neurological disorder and other endocrine abnormalities.

This comprehensive review provides the current research on PDE1 and its potential utility as a therapeutic target in diseases including the cardiovascular, pulmonary, metabolic, neurocognitive, renal, cancers and possibly others.

PDE1 is shown to be a regulator of beta-catenin and GSK3beta, factors that are part of an important pathway for cell growth. The paper also identifies phosphatase protein phosphatase 2A (PP2A) B56c as the effector protein regulated by PDE1.

Phosphodiesterase-1 (PDE1) is a versatile enzyme that has surprisingly received considerable attention as a possible therapeutic target in Alzheimer’s disease (AD) because it maintains the homeostasis of 3ʹ,5ʹ-cyclic adenosine monophosphate (cAMP) ...

As a Class 1 phosphodiesterase, PDE1 hydrolyzes the 3' bond of 3'-5'-cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Here, we review evidence for this family of enzymes as drug targets for development of therapies aimed to address disorders of the central nervous system (CNS) and of ...

In the past decades, numerous PDE1 inhibitors with structural diversities have been developed and patented by pharmaceutical companies, providing drug candidates for exploring novel disease indications of PDE1.

PDE1 is a generic term that describes a family of enzymes that require both Ca2+ and calmodulin for activity. In humans, PDE1s are encoded by three genes (PDE1A, PDE1B and PDE1C), with further complexity arising from differential mRNA splicing.

PDE1 (phosphodiesterase1) is a phosphodiesterase enzyme also known as calcium - and calmodulin -dependent phosphodiesterase. It is one of the 11 families of phosphodiesterase (PDE1-PDE11). PDE1 has three subtypes, PDE1A, PDE1B and PDE1C which divide further into various isoforms.

Sep 15, 2021 · Inhibition of PDE1 or PDE3, combined with cAMP synthesis activation, similarly enhances Ca v 1.2 current density and increases myocyte contraction. However, PDE1i minimally impacts [Ca 2+ ] SR and correspondingly displays greater negative sensitivity to nitrendipine-induced Ca v 1.2 blockade.